文献速递前列腺癌

三种遗传风险指标预测前列腺癌发病与死亡的表现:基于人群的前瞻性分析

Performance of Three Inherited Risk Measures for Predicting Prostate Cancer Incidence and Mortality: A Population-based Prospective Analysis.
PubMed 文献 · Eur Urol · 2020-11-28

三种指标均与发病显著相关且相互独立,加入GRS后可将高危男性识别比例额外提高22%,并提升发病与死亡区分度(C统计量分别从0.58升至0.67、0.65升至0.71)。

要点

  • GRS与家族史和罕见致病突变独立相关,可补充二者进行风险分层。
  • 家族史和罕见致病突变识别11%高危男性,加入GRS额外识别22%。
  • GRS使发病区分C统计量从0.58升至0.67,死亡从0.65升至0.71。

核心结论

  • 基于人群的前瞻性研究提示,GRS可补充家族史和罕见致病突变两种指南推荐的遗传风险指标,用于分层前列腺癌发病与死亡风险。

主要发现

  • 中位随访9.67年,发现6890例前列腺癌新发病例,其中419例死于前列腺癌。
  • 单变量分析中,家族史阳性vs阴性的发病RR为1.88(95%CI 1.75-2.01),罕见致病突变携带者vs非携带者为2.89(95%CI 1.89-4.25),GRS最高vs最低四分位为1.97(95%CI 1.87-2.07),均p<0.001。
  • 多变量分析中三种指标与发病的关联均独立。
  • 家族史和罕见致病突变识别11%的高危男性,加入GRS额外识别22%的高危男性。
  • 区分发病的C统计量从0.58升至0.67(p<0.001),区分死亡的C统计量从0.65升至0.71(p=0.002)。

临床怎么用

  • 在前列腺癌风险评估中,可考虑在家族史和罕见致病突变基础上加入GRS以改善风险分层。

局限性

  • 少数族裔患者数量少。
  • 死亡随访时间较短。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Single nucleotide polymorphism-based genetic risk score (GRS) has been developed and validated for prostate cancer (PCa) risk assessment. As GRS is population standardized, its value can be interpreted as a relative risk to the general population. OBJECTIVE: To compare the performance of GRS with two guideline-recommended inherited risk measures, family history (FH) and rare pathogenic mutations (RPMs), for predicting PCa incidence and mortality. DESIGN, SETTING, AND PARTICIPANTS: A prospective cohort was derived from the UK Biobank where 208 685 PCa diagnosis-free participants at recruitment were followed via the UK cancer and death registries. OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: Rate ratios (RRs) of PCa incidence and mortality for FH (positive vs negative), RPMs (carriers vs noncarriers), and GRS (top vs bottom quartile) were measured. RESULTS AND LIMITATIONS: After a median follow-up of 9.67 yr, 6890 incident PCa cases (419 died of PCa) were identified. Each of the three measures was significantly associated with PCa incidence in univariate analyses; RR (95 % confidence interval [CI]) values were 1.88 (1.75-2.01) for FH, 2.89 (1.89-4.25) for RPMs, and 1.97(1.87-2.07) for GRS (all p < 0.001). The associations were independent in multivariable analyses. While FH and RPMs identified 11 % of men at higher PCa risk, addition of GRS identified an additional 22 % of men at higher PCa risk, and increases in C-statistic from 0.58 to 0.67 for differentiating incidence (p < 0.001) and from 0.65 to 0.71 for differentiating mortality (p = 0.002). Limitations were a small number of minority patients and short mortality follow-up. CONCLUSIONS: This population-based prospective study suggests that GRS complements two guideline-recommended inherited risk measures (FH and RPMs) for stratifying the risk of PCa incidence and mortality. PATIENT SUMMARY: In a large population-based prostate cancer (PCa) prospective study derived from UK Biobank, genetic risk score (GRS) complements two guideline-recommended inherited risk measures (family history and rare pathogenic mutations) in predicting PCa incidence and mortality. These results provide critical data for including GRS in PCa risk assessment.

来源:Eur Urol,查看原文。版权归原作者所有。

引用

  1. Shi Z, Platz EA, Wei J, et al. Performance of Three Inherited Risk Measures for Predicting Prostate Cancer Incidence and Mortality: A Population-based Prospective Analysis. Eur Urol. 2020. PMID: 33257031. doi:10.1016/j.eururo.2020.11.014

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。